North and South Pavilion works completed
We are excited to share that the redevelopment works of the North Pavilion and South Pavilion of the Human Technopole campus have been completed.
The buildings, originally built for Expo Milano 2015 to accommodate exhibition space and restaurants will now host laboratory and office space as well as state-of-the-art facilities for life science research.
The North Pavilion works were completed in mid-March 2021. The ground floor of the pavilion will host HT’s Cryo-EM Facility and Light Microscopy Facility equipped with latest technologies. The first floor of the building will host an open space office setting with worksations for microscopy image analysis. The building has been adapted to meet the technical requirements of the microscopes, for example by managing the environmental conditions of the rooms and inserting special platforms to avoid vibrations and support the machines’ weight.
The South Pavilion works were completed in mid-April 2021. The full redevelopment of the building meets the engineering and testing needs of the laboratories and is in line with energy efficiency requirements. It will host lab spaces for Neurogenomics and Genomics and research activities as well as part of HT’s core facilities. It will have feature 60 and 90 workstations (depending on the final layout) and will link to Palazzo Italia, Human Technopole’s institutional headquarters, through a suspended tunnel.
Both buildings will now be furnished and set up to welcome Human Technopole researchers in the coming months.
Share:
You could also like:
-
Italy at the centre of the Genome of Europe project
The Human Technopole, ELIXIR Italia, the national node of the European life sciences research infrastructure coordinated by the National Research Council (CNR), and the Centro Cardiologico Monzino, as the Italian coordinating centre, have been selected as the Italian partners of Genome of Europe (GoE), the largest EU-funded genomic project, whose ultimate goal is to make […]
-
Human Technopole wins 2024 Oscar di Bilancio
On Friday 13 December, at Palazzo Mezzanotte in Milan, the Human Technopole Foundation’s ‘Integrated Report 2023’ received the Oscar di Bilancio in the social enterprises and non-profit organisations category. The award was presented to President Gianmario Verona, Elena Trovesi, Head of Administration, as well as the project leaders Giovanni Selmi, Head of Finance, and Alessandro […]
-
Mosaic Organoids to Study the Brains of Multiple Patients Simultaneously
An international team of scientists from Human Technopole and the University of Milan has developed and validated an innovative approach to studying human brain development across multiple individuals simultaneously using single organoids—laboratory models that replicate key cellular processes of human neurodevelopment. The research paves the way for in vitro population studies. Additionally, the scientists have developed a novel computational method to more accurately quantify the genetic identity of individual cells profiled from multiple individuals concurrently. The findings have been published in Nature Methods.
-
Cancer stem cell morphology predicts glioblastoma growth and resistance
Human Technopole researchers have identified adducin-γ (ADD3) as a crucial regulator of glioblastoma cancer stem cell morphology and intercellular bridges between tumour cells. These connections facilitate communication and allow tumour cells to share resources, evade chemotherapy, and survive in challenging conditions. The study has been funded by AIRC and the findings are published in Life Science Alliance.
-
Colorectal Cancer: ML Enhances Cetuximab Response Predictions
An international collaborative study led by Human Technopole, Candiolo Cancer Institute IRCCS in Turin, the University of Turin, and the Wellcome Sanger Institute in Cambridge (UK) has identified new factors associated with therapeutic response in colorectal cancer. The research has led to the development of a machine-learning model capable of accurately predicting the effects of cetuximab, a drug in clinical use, on different colorectal tumour subtypes. Funded by the AIRC Foundation, the study paves the way to identifying molecular features that could serve as biomarkers for predicting treatment response in patients with this type of cancer.